Biomarker & Intervention Discovery
Multiple Myeloma
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionEssentially zero; MGUS (precursor) progresses to myeloma in 1%/year; median survival without treatment <1 year once…
Best-intervention remissionDaratumumab + VRd (daratumumab + bortezomib + lenalidomide + dexamethasone) induction + autologous SCT: 66%…
Gap sizeModerate — outcomes dramatically improved but cure remains elusive; CAR-T access critical unmet need
Primary barrieraccess + biological
Full remission profile →
Remission & chronicity
Spontaneous remission
Essentially zero; MGUS (precursor) progresses to myeloma in 1%/year; median survival without treatment <1 year once symptomatic
Best-intervention remission
Daratumumab + VRd (daratumumab + bortezomib + lenalidomide + dexamethasone) induction + autologous SCT: 66% MRD-negative at 24 months (PERSEUS); CAR-T (idecabtagene vicleucel, ciltacabtagene autoleucel): 71-75% overall response, 28-33% CR in heavily pretreated patients; 5-year survival now ~55% (vs ~20% in 2000)
Gap size
Moderate — outcomes dramatically improved but cure remains elusive; CAR-T access critical unmet need
Primary barrier
access + biological
BCMA-targeted CAR-T therapy is transformative but manufacturing delays (6+ weeks), $420K+ cost, and limited centre access restrict use; bispecific antibodies (teclistamab) offer alternative; a functional cure remains an aspiration not a reality for most patients
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Multiple Myeloma” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."